The 2014 AHA/ACC guidelines on valvular heart disease are not an update of the previous 2008 version, but a completely new document. The guideline authors integrate the latest findings, in particular on novel transcatheter interventions, and also propose new strategies for risk assessment and shared decision-making through a multidisciplinary approach.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nishimura, R. A. et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation http://dx.doi.org/10.1161/CIR.0000000000000031.
Iung, B. & Vahanian, A. Epidemiology of valvular heart disease in the adult. Nat. Rev. Cardiol. 8, 162–172 (2011).
Rosenhek, R. et al. ESC Working Group on Valvular Heart Disease position paper: assessing the risk of interventions in patients with valvular heart disease. Eur. Heart J. 33, 822–828 (2012).
Vahanian, A. et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 33, 2451–2496 (2012).
Lancellotti, P. et al. ESC Working Group on Valvular Heart Disease position paper—heart valve clinics: organization, structure, and experiences. Eur. Heart J. 34, 1597–1606 (2013).
Turpie, A. G. et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N. Engl. J. Med. 329, 524–529 (1993).
Massel, D. & Little, S. H. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J. Am. Coll. Cardiol. 37, 569–578 (2001).
Habib, G. et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Eur. Heart J. 30, 2369–2413 (2009).
Duval, X. Simplification of the prophylaxis of endocarditis: we were right! Arch. Cardiovasc. Dis. 106, 69–71 (2013).
Iung, B. et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur. Heart J. 24, 1231–1243 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.I. declares that he has received consultant fees from Abbott, Boehringer Ingelheim, and Valtech; and speaker's fees from Edwards Lifesciences. A.V. declares that he is a member of the Advisory Board for Abbott and Valtech, and has received speaker's fees from Edwards Lifesciences and Siemens.
Rights and permissions
About this article
Cite this article
Iung, B., Vahanian, A. Implications of the new AHA/ACC valvular disease guidelines. Nat Rev Cardiol 11, 317–318 (2014). https://doi.org/10.1038/nrcardio.2014.42
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.42
